{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:31Z","timestamp":1787030131148,"version":"build-2736575974"},"reference-count":17,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["197785619\/SFB1021"],"award-info":[{"award-number":["197785619\/SFB1021"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["J59\/2018"],"award-info":[{"award-number":["J59\/2018"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leibniz Association","award":["197785619\/SFB1021"],"award-info":[{"award-number":["197785619\/SFB1021"]}]},{"name":"Leibniz Association","award":["J59\/2018"],"award-info":[{"award-number":["J59\/2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Lassa virus (LASV) can cause severe acute systemic infection in humans. No approved antiviral drugs or vaccines are currently available. Antibody-based therapeutics are considered a promising treatment strategy in the management of LASV disease. Methods: We used chimeric Ifnar\u2212\/\u2212 C57BL\/6 (Ifnar\u2212\/\u2212\u00a0Bl6) mice, a lethal LASV mouse model, to evaluate the protective efficacy of polyclonal antibodies purified from sera of rabbits hyperimmunized with virus-like particles displaying native-like LASV glycoprotein GP spikes. Results: Polyclonal anti-LASV GP antibodies provided 100% protection against lethal LASV infection in a pre- and post-exposure treatment setting and prevented LASV disease. Treatment also significantly lowered viremia level and virus load in organs. When treatment was initiated at the onset of symptoms, the hyperimmune antibodies provided partial protection and increased the survival rate by 80%. Conclusions: Our findings support the consideration of animal-derived hyperimmune antibodies targeting GP as an effective treatment option for highly pathogenic LASV.<\/jats:p>","DOI":"10.3390\/v15071436","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T01:42:02Z","timestamp":1687830122000},"page":"1436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-7485","authenticated-orcid":false,"given":"Lisa","family":"Oestereich","sequence":"first","affiliation":[{"name":"Department of Virology, Bernhard-Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infectious Research (DZIF), Partner Site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"M\u00fcller-Kr\u00e4uter","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pallasch","sequence":"additional","affiliation":[{"name":"Department of Virology, Bernhard-Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany"},{"name":"German Center for Infectious Research (DZIF), Partner Site Hamburg-L\u00fcbeck-Borstel-Riems, 20359 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7857-937X","authenticated-orcid":false,"given":"Thomas","family":"Strecker","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Asogun, D.A., Adomeh, D.I., Ehimuan, J., Odia, I., Hass, M., Gabriel, M., Olschlager, S., Becker-Ziaja, B., Folarin, O., and Phelan, E. (2012). Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: Lessons learnt from two years of laboratory operation. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001839"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aau9343","article-title":"Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak","volume":"363","author":"Kafetzopoulou","year":"2019","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","article-title":"Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: A retrospective, observational cohort study","volume":"18","author":"Okokhere","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","article-title":"Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis","volume":"87","author":"Eberhardt","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","article-title":"The use of Lassa fever convalescent plasma in Nigeria","volume":"78","author":"Frame","year":"1984","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41541-020-00219-x","article-title":"Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity","volume":"5","author":"Muller","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1128\/JVI.02240-09","article-title":"Viral protein determinants of Lassa virus entry and release from polarized epithelial cells","volume":"84","author":"Schlie","year":"2010","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Oestereich, L., Ludtke, A., Ruibal, P., Pallasch, E., Kerber, R., Rieger, T., Wurr, S., Bockholt, S., Perez-Giron, J.V., and Krasemann, S. (2016). Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005656"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ebiom.2017.12.010","article-title":"Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge","volume":"27","author":"Espinosa","year":"2018","journal-title":"eBioMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"24179","DOI":"10.1038\/srep24179","article-title":"Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1038\/s41598-022-07793-1","article-title":"Anti-SARS-CoV-2 equine F (Ab\u2019)2 immunoglobulin as a possible therapy for COVID-19","volume":"12","author":"Botosso","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/infdis\/jiv565","article-title":"Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection","volume":"213","author":"Dowall","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1473-3099(20)30737-4","article-title":"Factors associated with progression to death in patients with Lassa fever in Nigeria: An observational study","volume":"21","author":"Strampe","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1886560","DOI":"10.1080\/21645515.2021.1886560","article-title":"Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases","volume":"18","author":"Tharmalingam","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200969110-00007","article-title":"Rabbit antithymocyte globulin (thymoglobulin): A review of its use in the prevention and treatment of acute renal allograft rejection","volume":"69","author":"Deeks","year":"2009","journal-title":"Drugs"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:00:58Z","timestamp":1760126458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["v15071436"],"URL":"https:\/\/doi.org\/10.3390\/v15071436","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]}}}